Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (10195)	1/29/2004 9:36:31 AM
From: Biomaven	Respond to of 52153

The combo pill article is interesting in the context of SEPR's proposal to combine their Norvasc ICE with an ARB (angiotensin II receptor blocker). As I had speculated over on the SEPR thread, this proposal is interesting not least because it presumably assumes a partnership with one of the half-dozen or so existing pharma with ARBs on the market. So that might imply some relatively near-term news. At some point a pharma is also going to come up with an ARB/statin combo. There's an argument to be made that virtually all older people would benefit from that combo - the statins reduce inflammation and help with osteoporosis, while the ARB blocker likely helps with fibrosis of all sorts and do other good stuff as well. (Note that the good things I cite are quite distinct from the original purposes of these drugs, which of course are cholesterol lowering and reducing hypertension respectively). Peter

To: Doc Bones who wrote (10195)	1/29/2004 10:42:05 AM
From: tom pope	Read Replies (1) \| Respond to of 52153

Has anybody done GERN yet - you have a cow but it's not yours?